Skip to main content

Table 1 Parameters before and after transition to dolutegravir (N = 254)

From: Neuropsychiatric outcomes before and after switching to dolutegravir-based therapy in an acute HIV cohort

 

Pre-switchd

Post-switchd

p value

CD4+ T-cells (cells/μl)

624 (512–783)

662 (530–833)

< 0.001

CD8+ T-cells (cells/μl)

574 (449–787)

618 (482–797)

0.155

CD4/CD8

1.09 (0.85–1.41)

1.12 (0.87–1.43)

0.026

NPZ-4

0.70 (0.31–1.10)

0.88 (0.37–1.19)

< 0.001

Color Trails 1 z-score

1.15 (0.59–1.56)

1.30 (0.64–1.74)

0.001

Color Trails 2 z-score

0.61 (0.14–1.11)

0.86 (0.40–1.22)

< 0.001

Grooved pegboard test z-score

0.54 (− 0.20–1.05)

0.64 (− 0.09–1.10)

0.149

Trail making A z-score

0.75 (0.14–1.15)

0.80 (0.07–1.33)

0.037

PHQ-9 score

5 (1–7)

5 (2–8)

0.009

PHQ-9 ≥ 10, n (%)

24 (10)

40 (16)

0.006

PHQ-9 ≥ 15, n (%)

8 (3)

8 (3)

1.000

PHQ-9 somatic sub-scorea

2 (0–3)

2 (1–3)

0.007

PHQ-9 cognitive/affective sub-scoreb

2 (0–4)

2 (0–5)

0.064

Major depression by 2Q-depression screening, n (%)

2 (1)

3 (1)

1.000

Distress thermometer score

2 (1–5)

2 (1–4)

0.898

Viral suppression, n (%)c

244 (96)

250 (98)

0.070

  1. NPZ-4 Composite z-score of the 4 neuropsychiatric tests, PHQ-9 Patient Health Questionnaire-9
  2. aQuestions 3, 4, 5
  3. bQuestions 1, 2, 6, 7, 8, 9
  4. cDefined as plasma HIV RNA < 50 copies/ml
  5. dMedian (IQR) is presented unless specified; Wilcoxon and McNemar test were used accordingly